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Abstract 20 
The novel ATP synthase inhibitor bedaquiline recently received accelerated approval for 21 
treatment of multidrug-resistant tuberculosis and is currently being studied as a component of 22 
novel treatment-shortening regimens for drug-susceptible and multidrug-resistant tuberculosis. In 23 
a limited number of bedaquiline-treated patients reported to date, upward shifts of ≥4-fold in 24 
bedaquiline MIC during treatment have been attributed to non-target-based mutations in Rv0678 25 
that putatively increase bedaquiline efflux through the MmpS5-MmpL5 pump. These mutations 26 
also confer low-level clofazimine resistance, presumably by similar mechanism. Here, we 27 
describe a new non-target-based determinant of low-level bedaquiline and clofazimine cross-28 
resistance in Mycobacterium tuberculosis: loss-of-function mutations in pepQ (Rv2535c), a 29 
putative Xaa-Pro aminopeptidase. pepQ mutants were selected in mice by treatment with 30 
clinically relevant doses of bedaquiline, with or without clofazimine, and were shown to have 31 
bedaquiline and clofazimine MICs 4 times higher than parental H37Rv strain. Co-incubation 32 
with efflux inhibitors verapamil/reserpine lowered bedaquiline MICs against both mutant and 33 
parent strains to a level below the MIC against H37Rv in the absence of efflux pump inhibitors. 34 
However, qPCR revealed no significant differences in expression of Rv0678, mmpS5 or mmpL5 35 
between mutant and parent strains. Complementation of a pepQ mutant with wild-type gene 36 
restored susceptibility, indicating loss of pepQ function is sufficient for reduced susceptibility 37 
both in vitro and in mice. Although the mechanism by which mutations in pepQ confer 38 
bedaquiline and clofazimine cross-resistance remains unclear, these results may have clinical 39 
implications and warrant further evaluation of clinical isolates with reduced susceptibility to 40 
either drug for mutations in this gene.  41 
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 3 
 
Introduction 42 
Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global control of 43 
tuberculosis (TB). When multidrug resistance is not diagnosed, patients respond poorly to 44 
standardized first-line regimens and additional resistance may develop. When MDR-TB is 45 
diagnosed, current second-line regimens require prolonged treatment durations and are less 46 
effective, more toxic and far more expensive than first-line therapy (1).  47 
The diarylquinoline drug bedaquiline (B) received accelerated approval from the U.S. 48 
Food and Drug Administration as part of combination therapy for MDR-TB when other 49 
alternatives are not available (2). It is now being studied as a component of novel short-course 50 
regimens for MDR as well as drug-susceptible TB (ClinicalTrials.gov Identifiers: 51 
NCT02333799, NCT02193776, NCT02589782, NCT02409290, NCT02454205 52 
[https://clinicaltrials.gov/]).  For new drugs such as bedaquiline, it is essential to define and 53 
catalog the mechanisms conferring bacterial resistance in order to design appropriate diagnostic 54 
tests (including rapid molecular tests), to better manage the treatment of patients who fail therapy 55 
or relapse after receiving the drug, and to conduct population level surveillance for changes in 56 
drug susceptibility.  57 
 The principal mechanism of action of bedaquiline is inhibition of the mycobacterial ATP 58 
synthase (3, 4). Strains selected in vitro for resistance to bedaquiline often have mutations in 59 
atpE, which encodes the ATP synthase subunit to which bedaquiline binds (5). These target-60 
based mutations cause relatively large (i.e., 10-128x) shifts in MIC. However, it was noted that 61 
many bedaquiline -resistant isolates selected in vitro, typically with smaller shifts in MIC, do not 62 
have mutations in the ATP synthase complex (5). A new non-target-based mechanism conferring 63 
low-level bedaquiline resistance and cross-resistance to clofazimine (C) was recently identified 64 
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among isolates from patients with delayed sputum culture conversion while receiving 65 
bedaquiline for MDR-TB, among mice treated with bedaquiline-containing combinations, and in 66 
vitro (6, 7). Although both bedaquiline and clofazimine (7) can select for non-target-based 67 
mutants in vitro, such mutants have not yet been isolated from mice or patients treated with 68 
clofazimine. The responsible mutations were found in Rv0678, which encodes a negative 69 
regulator of mmpL5 and mmpS5. Increased transcription of these genes, which comprise a 70 
membrane transporter in the resistance-nodulation-division (RND) family, is putatively 71 
associated with increased efflux of bedaquiline and clofazimine.  72 
Identification of mutations conferring cross-resistance to clofazimine and bedaquiline is 73 
important because clofazimine is a component of some short-course regimens currently under 74 
study for treatment of MDR-TB (8-10)  and both drugs are being used together in the ongoing 75 
STREAM trial (ClinicalTrials.gov identifier: NCT02409290 [https://clinicaltrials.gov/]). Herein, 76 
we report a new genetic determinant of low-level bedaquiline and clofazimine cross-resistance in 77 
M. tuberculosis, conferred by mutations in pepQ.  78 
 79 
 80 
Materials and Methods 81 
Bacterial strains.  M. tuberculosis H37Rv was passaged in mice, sub-cultured in Middlebrook 82 
7H9 (Fisher Scientific) supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC) 83 
complex (Becton-Dickinson) and 0.05% Tween 80 (Sigma-Aldrich) and used for aerosol 84 
infection when the optical density at 600 nm (O.D. 600) was approximately 1.0.  85 
 86 
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Antimicrobials. Pretomanid (Pa), moxifloxacin (M), bedaquiline and linezolid (L) were 87 
provided by the Global Alliance for Tuberculosis Drug Development (New York, NY), Bayer 88 
(Leverkusen, Germany), Janssen (Beerse, Belgium) and Pfizer (Groton, CT), respectively. 89 
Rifampin (R), isoniazid (H), pyrazinamide (Z), ethambutol (E), and clofazimine were purchased 90 
from Fisher or Sigma. Dosing formulations were prepared and maintained as previously 91 
described (11). All drugs were administered once daily by gavage, 5 days per week. 92 
 93 
Aerosol infection. Female BALB/c mice (Charles River, Wilmington, MA) aged 4-to-6 weeks 94 
were infected by the aerosol route using the Inhalation Exposure System (Glas-col Inc., Terre 95 
Haute, IN). Mice were randomized to treatment groups (five mice per group per time point) after 96 
aerosol infection and were routinely sacrificed (i) on the day after infection to determine the 97 
number of colony-forming units (CFU) implanted in the lungs, (ii) on the day of treatment 98 
initiation to determine the pre-treatment CFU count, and (iii) at selected time points during and 99 
after treatment. Quantitative cultures of lung homogenates were performed in parallel on 100 
selective 7H11 agar with and without 0.4% activated charcoal to reduce drug carryover effects, 101 
as previously described (11). All procedures involving animals were approved by the Animal 102 
Care and Use Committee of Johns Hopkins University. 103 
 104 
Efficacy of combinations containing bedaquiline and clofazimine in murine models of TB. 105 
Beginning 14 days after high-dose aerosol infection, as previously described (12), BALB/c mice 106 
received no treatment (negative controls) or treatment with the first-line regimen of RHZ 107 
(positive controls) or one of the following test regimens: bedaquiline (25 mg/kg) alone, the two-108 
drug combination of bedaquiline plus clofazimine (20 mg/kg), or three-drug combinations of 109 
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bedaquiline plus clofazimine plus one of the following: rifampin (10 mg/kg), isoniazid, (10 110 
mg/kg), pyrazinamide (150 mg/kg),  ethambutol (100 mg/kg), moxifloxacin (100 mg/kg), 111 
pretomanid (50 mg/kg) and linezolid (100 mg/kg). Lung CFU counts were determined for all 112 
treatment groups after 4 weeks of treatment and, for mice receiving bedaquiline alone and 113 
bedaquiline plus clofazimine, also after 6 and 8 weeks of treatment. 114 
 115 
MIC determination. Determination of bedaquiline and clofazimine MICs and the proportion of 116 
drug-resistant mutants was performed using the agar proportion method. Serial dilutions of lung 117 
homogenates, colony suspensions or a broth culture were inoculated in 500 µl aliquots onto 118 
7H11 plates with and without the indicated drug. MICs were determined using doubling 119 
bedaquiline and clofazimine concentrations ranging from 0.003 to 0.25 µg/ml and 0.06 to 2 120 
µg/ml, respectively. MIC was defined as the lowest drug concentration inhibiting at least 99% of 121 
the growth observed on drug-free control plates. To investigate the effect of efflux pump 122 
inhibitors on the susceptibility of the strains, the MIC of bedaquiline was also determined using 123 
the broth macrodilution method. Doubling concentrations of bedaquiline from 0.007 to 1 µg/ml 124 
were tested in the presence or absence of 40 µg/ml verapamil or 3 µg/ml reserpine. Briefly, tubes 125 
containing in 2.5 ml of 7H9 broth plus OADC with the above concentrations of bedaquiline were 126 
inoculated with 105 CFU of log phase culture of H37Rv or the B5 mutant. MIC was defined as 127 
the lowest concentration that prevented visible growth after 14 days of incubation at 37ºC. 128 
Controls with and without efflux inhibitors and bedaquiline were included for each test. The 129 
experiment was performed twice. 130 
  131 
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DNA sequencing. Genomic DNA from the parental wild-type strain and resistant mutants was 132 
extracted by using the cetyltrimethylammonium bromide (CTAB) protocol (13) and sonicated 133 
(Covaris, Inc.). The DNA library was constructed by using a genomic DNA sample preparation 134 
kit (Illumina, Inc.). The samples were sequenced on an Illumina Genome Analyzer II, which was 135 
operated in paired-end mode, collecting pairs of 51bp reads from opposite ends of ~250-350bp 136 
fragments. Image analysis and base-calling were done by using the Illumina GA Pipeline 137 
software (v0.3). Genome assembly was performed by a comparative assembly method using 138 
software developed in house. Briefly, reads were aligned to the genome of H37Rv as a reference 139 
sequence, and then local contig-building was used to identify insertions/deletions (14). Mutations 140 
in pepQ (Rv2535c) were confirmed by PCR amplification using specific primers (Table S1 in the 141 
supplemental material). 142 
 143 
In vivo confirmation of low-level cross-resistance to bedaquiline and clofazimine. BALB/c 144 
mice were infected with either the H37Rv parent strain or an isogenic strain (B5) with a non-145 
synonymous pepQ mutation and randomized to receive no treatment, isoniazid (10 mg/kg) alone, 146 
bedaquiline (12.5, 25, or 50 mg/kg) alone, clofazimine (20 mg/kg) alone, or bedaquiline at 25 147 
mg/kg plus clofazimine. Treatment began 4 days after infection and was administered for 4 148 
weeks for all groups, except the bedaquiline 25 mg/kg groups, which received 8 weeks of 149 
treatment.   150 
 151 
Complementation studies to confirm that a pepQ mutation is sufficient for bedaquiline and 152 
clofazimine cross-resistance. The B5 strain was complemented with pDT-Rv2535c (Figure S1 153 
in the supplemental material) containing the wild-type pepQ gene from H37Rv. 154 
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Complementation was confirmed by showing loss of susceptibility to hygromycin and PCR for 155 
presence of the hygromycin resistance gene. Bedaquiline and clofazimine MICs were determined 156 
in vitro. Following aerosol infection with the H37Rv parent strain, the B5 mutant, or the B5: 157 
pepQ complemented strain, BALB/c mice were randomized to receive no treatment, isoniazid 10 158 
mg/kg, bedaquiline 25 mg/kg, or clofazimine 20 mg/kg. Treatment began three days after 159 
infection and continued for 4 weeks before mice were sacrificed to determine lung CFU counts. 160 
Expression analysis of mmpS5, mmpL5 and Rv0678: 161 
The H37Rv parent strain and the B5 mutant were grown to mid-log phase (OD600 = 0.6) in 7H9 162 
broth and cells were pelleted by centrifugation. RNA was extracted by bead beating in Trizol and 163 
column purified according to the manufacturer's instructions (Qiagen, Valencia, California). 164 
RNA was reverse-transcribed using the iScript Reverse Transcription Supermix (Bio-Rad, 165 
Hercules, CA). Real time PCR was performed with iQ SYBR Green supermix on a iCycler 166 
(BioRad, Hercules, CA) using primers specific for Rv0676c, Rv0677c and Rv0678 and 16S 167 
rRNA (Table S1 in the supplemental material). All experiments were performed in biological 168 
and technical triplicates. Cycle threshold values were normalized against 16S rRNA expression, 169 
and fold-change was calculated by the −2ΔΔCt method (15). 170 
 171 
 Expression, purification and activity assays of pepQ. The entire coding region of Rv2535c 172 
was cloned into pET28b expression vector (Novagen) containing an in-frame N-terminal 6x-His 173 
tag with the TEV cleavage site using the NdeI and HindIII restriction sites. The plasmid was 174 
transformed into BL21(DE3) E.coli cells for expression of Rv2535c. Cells containing the 175 
plasmid were grown at 37̊℃ for 7 hours in LB medium with 50 μg/ml kanamycin followed by 176 
induction with 1 mM IPTG and grown overnight at 18℃. The cells were lysed via a 177 
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Microfluidizer M-100P (Microfluidics, Worcestershire, UK) in lysis buffer (50 mM Tris, pH 7.5, 178 
500 mM NaCl, 5% glycerol, DNase, and 2 mM MgCl2) and centrifuged at 15,000 rpm for 1 179 
hour. The supernatant was chromatographed over a His-tag affinity column (GE Healthcare) 180 
charged with Ni. The protein was eluted with 0 to 300 mM imidazole gradient and the 6x-His tag 181 
was cleaved using the tobacco etch virus protease. The final purification step was gel-filtration 182 
chromatography, and on the standardized s200 Superdex (GE Healthcare) column. pepQ eluted 183 
in two peaks: a large molecular weight aggregate that came out near the void volume, followed 184 
by a distinct peak with calculated molecular weight corresponding to a tetramer (~160 KDa). 185 
Formation of this tetramer is consistent with other related proteins, e.g. PDB ID 3Q6D. The 186 
protein was >95% pure, as observed by SDS-PAGE, and was concentrated to 7.5 mg/ml, flash 187 
frozen, and stored in dialysis buffer (50 mM Tris, pH 7, 50 mM NaCl, 5% glycerol, 1 mM DTT) 188 
at -80℃. The purified recombinant pepQ tetramer in 50mM Tris pH 7 was tested for both 189 
creatinase activity using the creatinase assay kit (Sigma) and for endopeptidase activity using 190 
commercially available fluorescent peptides. As the peptides were all labeled with a p-191 
nitroanilide group the assay monitored for a shift in absorbance at 410 nm, resulting from the 192 
cleaved product.    193 
    194 
Statistical analysis. CFU counts were log10 transformed before analysis. Group means for 195 
experimental treatment groups were compared with that of the standard treatment control by one-196 
way analysis of variance (ANOVA) with Dunnett’s post-test to adjust for multiple comparisons. 197 
All analyses were performed with GraphPad Prism v.4.01 (GraphPad, San Diego, CA). 198 
 199 
Results 200 
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Bedaquiline and clofazimine have additive activity against M. tuberculosis in mice but 201 
select for cross-resistant mutants. Using a well-established high-dose aerosol model of TB in 202 
mice, we evaluated the activity of novel drug combinations containing bedaquiline and 203 
clofazimine (Figure 1). Consistent with prior observations (11, 16, 17), treatment with the 204 
standard first-line RHZ regimen reduced the mean lung CFU count by 2.46 log10 over the first 4 205 
weeks and treatment with bedaquiline alone reduced the lung CFU counts by an additional 1.08 206 
log10. The addition of pyrazinamide and clofazimine each significantly increased the activity of 207 
bedaquiline (p< 0.001), whereas the addition of pretomanid had antagonistic effects (p< 0.05). 208 
The addition of rifampin, isoniazid, ethambutol or moxifloxacin did not significantly affect the 209 
activity of the bedaquiline-clofazimine combination, whereas addition of pyrazinamide 210 
significantly increased the activity (p< 0.001) and addition of linezolid or pretomanid reduced 211 
the activity (p< 0.05). After 8 weeks of treatment, 2 of 5 mice receiving bedaquiline alone had 212 
more than 3 log CFU in the lungs, while the mean log CFU count was 0.98 ± 0.53 in the 213 
remaining 3 mice. Likewise, 3 of 5 mice receiving bedaquiline plus clofazimine had the mean 214 
log CFU count of 2.12 ± 0.69, while the remaining 2 mice were culture-negative, as were all 5 215 
mice treated for just 6 weeks (Figure 1 inset). Unlike those from mice with lower CFU counts at 216 
week 8, the isolates from the lungs of mice with higher CFU counts grew equally well on 7H11 217 
agar with and without activated charcoal, indicating that their growth was not impaired by 218 
bedaquiline or clofazimine carried over in the lung homogenates.   219 
Whereas bedaquiline and clofazimine MICs for the wild-type H37Rv parent strain were 220 
0.03 and 0.25 µg/ml respectively, MICs for the isolates from the 2 mice treated with bedaquiline 221 
alone for 8 weeks (named B4 and B5) and the 3 mice treated with bedaquiline plus clofazimine 222 
for 8 weeks (named BC2, BC3 and BC4) with high, outlying lung CFU counts were 0.12-0.25 223 
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and 0.5-1 µg/ml, respectively, indicating that treatment with bedaquiline, with or without 224 
clofazimine, selected for strains with reduced susceptibility to both drugs. 225 
 226 
Isolates with bedaquiline and clofazimine cross-resistance harbored mutations in pepQ. 227 
Duplicate samples of genomic DNA from four cross-resistant strains isolated in the first mouse 228 
experiment (i.e., B5, BC2, BC3 and BC4) were sequenced on an Illumina GenomeAnalyzer IIx 229 
in paired-end mode using a read length of 51 bp. The mean depth of coverage ranged from 118 230 
to 161x (number of reads covering each site, averaged over the whole genome), and the 231 
completion was >99% (fraction of sites in 4.4 Mb genome covered by at least 1 read; sites 232 
lacking coverage were primarily restricted to PPE and PE_PGRS genes, due to very high GC 233 
content). The parental strain used in these experiments (H37RvJH) was also sequenced, to 234 
identify any differences from the public reference genome sequence for H37Rv (18). When 235 
compared to the sequence of the parental strain, only one mutation was observed in each strain 236 
(Table 1). All 4 strains had a mutation in pepQ (Rv2535c), which encodes a putative cytoplasmic 237 
peptidase. The mutations observed included 2 frameshift mutations (-C in Arg271, +C in Ala14) 238 
in mice treated with the bedaquiline-clofazimine combination, as well as a non-synonymous 239 
single nucleotide polymorphism causing a Leu44Pro mutation, obtained from a mouse treated 240 
with bedaquiline alone. All mutations were confirmed by PCR amplification and sequencing.  241 
 242 
A pepQ mutant is virulent and less susceptible to bedaquiline and clofazimine in a murine 243 
TB model. Because transposon mutagenesis experiments have suggested that inactivation of 244 
pepQ may reduce the fitness of M. tuberculosis (19), and because the pepQ mutants displayed 245 
only low-level resistance to bedaquiline and clofazimine in vitro, we sought to confirm their 246 
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virulence and reduced susceptibility in vivo. We compared the parental H37Rv strain and the B5 247 
mutant on the basis of their ability to multiply in untreated BALB/c mice and their susceptibility 248 
to treatment with isoniazid (positive control), bedaquiline, and/or clofazimine. The aerosol 249 
infectious dose was approximately 1 log10 higher for the parent strain compared to the B5 mutant 250 
(Figure 2). By 4 weeks post-infection, untreated (UT) control mice infected with H37Rv had 251 
died and therefore none were available for CFU counts (although lung CFU counts are typically 252 
> 8 log10, or approximately 4 log10 higher than baseline, at the time of death). Untreated mice 253 
infected with B5 did not die within 4 weeks of infection because the infectious dose was not high 254 
enough. However, the approximately 4 log10 increase in lung CFU counts over this time period is 255 
evidence that the strain multiplies more-or-less normally in mice. The treatment with isoniazid 256 
(positive control) was at least as bactericidal against the B5 strain as against H37Rv, reducing the 257 
lung CFU counts by more than 1 log10 in both strains. Dose-dependent activity of bedaquiline 258 
was observed against both strains. However, whereas bedaquiline 12.5 mg/kg was bacteriostatic 259 
and 50 mg/kg reduced the lung CFU counts by more than 2 log10 against H37Rv, even 50 mg/kg 260 
of bedaquiline did not fully inhibit multiplication of the B5 mutant but rather allowed a nearly 2 261 
log10 increase in CFU counts. Clofazimine enabled growth of both strains in this acute infection 262 
model, as previously observed (20), but was more effective against the H37Rv strain compared 263 
to the B5 mutant.   264 
 265 
Complementation of pepQ restores susceptibility to bedaquiline and clofazimine. 266 
Complementation of the B5 and BC2 strains with the wild-type pepQ gene from H37Rv restored 267 
the susceptibility of the strains to bedaquiline, as confirmed by the MIC of 0.03 µg/ml, which 268 
was no different from the parental H37Rv control. Following this, 3 groups of mice were infected 269 
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 13 
 
with H37Rv, the B5 strain, or the B5::pepQ strain and initiated on treatment with isoniazid 10 270 
mg/kg, bedaquiline 25 mg/kg, or clofazimine 20 mg/kg four days later. In untreated mice, lung 271 
CFU counts increased by approximately 4 log10 over the subsequent 4 weeks (Figure 3) and were 272 
accompanied by visible lung lesions (Figure S2 in the supplemental material). Isoniazid was 273 
bactericidal, with the greatest effect against the B5 strain, and prevented the formation of lung 274 
lesions. Like isoniazid, bedaquiline reduced the mean lung CFU counts by 0.5-1 log10 CFU 275 
against H37Rv and B5:pepQ, and it did prevent formation of macroscopic lung lesions in mice 276 
infected with the B5 mutant (Figure S2 in the supplemental material). However, bedaquiline 277 
allowed a >1 log10 increase in mean CFU counts of the B5 mutant. Clofazimine, which has a 278 
relatively poor activity in this acute infection model when given alone (20), allowed 279 
multiplication of all strains but significantly reduced the multiplication of the H37Rv (p < 0.05) 280 
and B5:pepQ (p < 0.05) strains, but not the B5 strain (p > 0.05) when compared to no treatment. 281 
In addition, clofazimine prevented formation of lung lesions in mice infected with H37Rv and 282 
the B5:pepQ complemented strain, but not the B5 strain (Figure S2 in the supplemental 283 
material). These results clearly demonstrate that complementation with the wild-type pepQ gene 284 
was sufficient to restore susceptibility to bedaquiline and clofazimine in the B5 mutant and thus 285 
confirm the loss of pepQ function is sufficient for low-level resistance to bedaquiline and 286 
clofazimine. 287 
 288 
Structural analysis of M. tuberculosis pepQ. pepQ is a 372-amino-acid protein that has two 289 
domains: a ~100 aa N-terminal alpha/beta domain, and a ~250-aa C-terminal peptidase domain 290 
(Figure 4). Based on homology to Ypdf in E. coli (e.g. 37% amino acid identity over 363 291 
residues), M. tuberculosis pepQ is predicted to be a proline-specific aminopeptidase (prolidase), 292 
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active on substrates with Xaa1-Pro2 at the amino terminus. The C-terminal domain of YpdF 293 
houses the catalytic activity, and is homologous to the E. coli methionine aminopeptidase 294 
(MetAP; 29% aa identity) (21). However, MetAP lacks the N-terminal domain. In enzyme 295 
assays, YpdF was found to have weak activity on substrates with an N-terminal methionine 296 
(Met-Xaa) if the second aa is alanine, proline or serine, and higher activity for other substrates 297 
with a proline in the second position (Xaa-Pro) (22). In E. coli, YpdF is encoded in an operon 298 
with YpdE, which is a methionine aminopeptidase. YpdF and YpdE are proposed to work in 299 
concert to degrade proteins, with YpdE removing amino acids from the N-terminus until a 300 
proline is encountered in the 2-position, and YpdF removing the block (22). M. tuberculosis 301 
pepQ also has homology (~30% aa identity) to other E. coli proline aminopeptidases, pepP and 302 
pepQ, which have both the catalytic C-terminal domain and a non-catalytic N-terminal domain 303 
that plays a role in oligomerization and substrate specificity. pepP and similar aminopeptidase P 304 
enzymes (EC 3.4.11.9) may preferentially hydrolyze the Xaa-Pro bond at the terminus of larger 305 
oliogopeptides (but also dipeptides) and can discriminate the 3rd and 4th residues in their 306 
catalytic specificity. 307 
Proline aminopeptidases have similar 2-domain architecture to creatinases (which 308 
catalyze a similar reaction, hydrolysis of creatine into sarcosine and urea), although peptidase 309 
activity of the former is metal-ion dependent and they bind cations in the active site (21), 310 
whereas creatinase activity does not require metal ions (23, 24). The mutations selected by 311 
treatment with bedaquiline ± clofazimine in mice occurred in both domains. The frameshift 312 
mutation in Ala14 and the non-synonymous mutation L44P occur in the N-terminal domain, and 313 
the frameshift mutation in Arg271 occurs in the catalytic domain. Figure 4 illustrates where these 314 
mutations fall in the domain structure of pepQ. To better understand the role of these mutations, 315 
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 15 
 
we used Phyre2 (25) to build a homology model of the 3D atomic structure pepQ. Phyre2 316 
detected the greatest homology to a proline aminopeptidase from B. anthracis (PDB: 3q6d, 39% 317 
amino acid identity; deposited by Midwest Center for Structural Genomics). Phyre2 created a 318 
hidden Markov model based on a Psi-BLAST alignment of closely related sequences and used it 319 
to optimally thread the M. tuberculosis pepQ amino acid sequence onto the 3q6d structure as a 320 
template, followed by loop optimization and energy minimization (25). The active site can be 321 
inferred to be in a pocket in the C-terminal domain containing a Ca2+ metal ion, in the same 322 
position as the dinuclear divalent cation sites in pepP (1a16) and MetAP (3mat), which is 323 
involved in catalyzing the cleavage of the scissile peptide bond. The cations are coordinated by 324 
D221, D232, E339, E325, and His296 (Mtb pepQ), all perfectly conserved in all of these 325 
structures. Based on the homology model, Leu44 of M. tuberculosis pepQ appears buried in the 326 
core of the N-terminal domain (on a beta strand that shows a high level of conservation with E. 327 
coli pepP and both prokaryotic and eukaryotic prolidases, (26) not in close proximity to the 328 
active site. Thus, L44P is likely a structure-destabilizing mutation, as is the frameshift mutation 329 
in Ala14. A frameshift in Arg271 would truncate half the C-terminal domain (splitting the 330 
pseudo-symmetric alpha/beta “pita-bread” fold in half and destroying the active site).   331 
 The pepQ model can be superimposed with the crystal structure of the E. coli MetAP 332 
protein (3mat), which was complexed with a peptide inhibitor (bestatin analog). The mechanism 333 
and specificity determinants of E. coli MetAP have been well characterized (21). MetAP has a 334 
dinuclear cation site (2 Co2+) in the same location as in 3q6d. The N-terminal residue of the 335 
peptide inhibitor of MetAP binds in a P1 pocket, and the second residue binds in a P2 pocket, 336 
with the polar backbone atoms of the scissile bond between them coordinating the cations. The 337 
residues of M. tuberculosis pepQ lining the P1 part of the pocket are considerably different than 338 
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MetAP. For example F190 is replaced with Cys in MetAP, and I302 is replaced with F. This 339 
could potentially explain differences in specificity for the N-terminal residue between prolidases 340 
and methionine aminopeptidases (27). While the inhibitor in the 3mat structure mimics Met1-341 
Ala2, YpdF would be expected to bind Xaa1-Pro2 as a prolidase. The putative position of the P2 342 
pocket can also be inferred by superimposing the crystal structure of E. coli pepP in complex 343 
with the inhibitor Pro-Leu (PDB: 1a16), which putatively mimics the 2nd and 3rd residues of a 344 
peptide substrate. In both MetAP and pepP, the P2 pocket is adjacent to residue His-204. While 345 
the homology between M. tuberculosis pepQ and E. coli pepP is relatively low (31% aa identity), 346 
nearly every residue in the vicinity of the active site was either identical or highly conserved. 347 
The residues lining the P1 pocket are F190 (Y), I302 (V), H303, T341 (D), T232, and V398 (L), 348 
with residues of E. coli pepP shown in parentheses. The residues lining P2 are T234, I193, R337, 349 
H204, P203 (L), and H292 (Figure 5). Thus we expect M. tuberculosis pepQ to be able to 350 
coordinate metal ions similar to E. coli pepP, and the specificity of M. tuberculosis pepQ to be 351 
very similar to E. coli pepP, i.e. a proline aminopeptidase (Xaa-Pro). 352 
 353 
Enzymatic characterization of M. tuberculosis pepQ.  354 
Recombinant purified M. tuberculosis pepQ exhibited no creatinase activity (data not shown). Of 355 
the 6 proline-containing peptide substrates tested, only Arg-Pro-p-nitroanilide showed modest 356 
cleavage activity.  Several substrates with an N-terminal methionine were also tested. However, 357 
none of these showed cleavage, suggesting pepQ is not a methionine aminopeptidase. 358 
 Mass spectrometry showed that recombinant M. tuberculosis pepQ does not bind to or 359 
modify the structure of bedaquiline or clofazimine.  Over-expression of M. tuberculosis pepQ in 360 
Mycobacterium smegmatis did not significantly alter the MIC of bedaquiline or clofazimine. 361 
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This is not surprising as the mutations presumably result in loss of function. Taken together, 362 
these results suggest pepQ is not a target or activating enzyme for either drug.  363 
 364 
Resistance mediated by pepQ mutation may be associated with increased drug efflux, but 365 
this is not due to up-regulation of mmpL5 and mmpS5 expression. 366 
Addition of verapamil and reserpine reduced the MIC against the H37Rv parent strain from 0.03 367 
to 0.007 µg/ml and 0.015- 0.03 µg/ml respectively. Both efflux inhibitors reduced the MIC of 368 
both the B5 mutant and the H37Rv parent to the same level that was below the MIC against the 369 
parent strain in the absence of the efflux inhibitor, indicating a possible role of one or more 370 
efflux pumps in the mechanism of low-level bedaquiline resistance mediated by loss-of-function 371 
mutations in pepQ (Table S2 in the supplemental material). Further, qPCR for the genes involved 372 
in the efflux-mediated resistance reported in previous studies did not show any significant fold 373 
change in transcription levels (Table S3 in the supplemental material). 374 
 375 
Discussion 376 
 Bedaquiline is a promising new drug for the treatment of TB. Its limited clinical usage to 377 
date has provided little opportunity to select for drug-resistant mutants or to assess the impact of 378 
such mutants on treatment outcomes. In vitro-selected target-based mutations in atpE confer 379 
high-level resistance to bedaquiline (e.g., 16-128x increase in MIC)(5, 6). However, to our 380 
knowledge, no atpE mutant has been isolated from a patient treated with bedaquiline. On the 381 
other hand, non-target mutations in Rv0678 conferring low-level resistance to bedaquiline and 382 
clofazimine were recently described in sputum isolates with at least 4-fold increases in 383 
bedaquiline MIC after treatment including bedaquiline (6). More recently, Rv0678 mutants were 384 
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identified in the sputum of both MDR-TB and drug-susceptible TB patients that had not received 385 
bedaquiline or clofazimine (28). Although these Rv0678 mutations cause relatively small (2-8x) 386 
increases in bedaquiline and clofazimine MICs compared to mutations in atpE, their selection 387 
during combination therapy in TB patients and in mice is a cause of concern (6). In mice, 388 
Rv0678 resistant mutants may be selected with 8 weeks of bedaquiline monotherapy (D. 389 
Almeida, unpublished observation) but emerge only late in the course of combination therapy 390 
and are eventually cleared, presumably by the action of companion agents (6). Clinically, these 391 
mutants emerged almost entirely among patients with pre-XDR- and XDR-TB (6) but their 392 
isolation has not clearly been associated with poorer clinical outcomes among patients receiving 393 
bedaquiline with more effective companion agents (29). These results underscore the importance 394 
of appropriate combination therapy and adherence, and the risk of premature discontinuation of 395 
therapy.  396 
The present study provides the first evidence of non-target mutations in pepQ conferring 397 
low-level resistance to bedaquiline and cross-resistance to clofazimine. Zhang et al (30) recently 398 
reported in vitro selection of a pepQ mutant in M. tuberculosis with clofazimine. However, they 399 
did not report the results of direct susceptibility testing with clofazimine or bedaquiline, or 400 
confirm the causative role of pepQ mutation in clofazimine resistance. Like mutations in Rv0678 401 
(6), the observed pepQ mutations produce modest increases (up to 4-fold) in bedaquiline and 402 
clofazimine MICs and reduce the efficacy of bedaquiline and clofazimine in vivo. However, 403 
these mutations did not result in complete resistance to these drugs, as increasing doses of 404 
bedaquiline and, to a lesser extent, combining bedaquiline and clofazimine were associated with 405 
greater anti-tuberculosis effect. These data and the additive bactericidal and sterilizing effects of 406 
bedaquiline and clofazimine against drug-susceptible bacilli (31) indicate that, despite the 407 
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presence of two shared resistance mechanisms, the combined use of clofazimine and bedaquiline 408 
may be advantageous. However, these two drugs will not protect each other against the 409 
emergence of resistance and it is therefore important to use them in combination only if they are 410 
protected from emergence of resistance by additional antibiotics that are not substrates of the 411 
same efflux pumps. Both Rv0678 and pepQ mutants are selected and able to grow in mice treated 412 
with bedaquiline, despite plasma bedaquiline concentrations exceeding the MIC against these 413 
resistant (11, 32) organisms. This may be due to the high protein binding of bedaquiline, which 414 
results in free drug concentrations below the MIC at the site of infection. Rv0678 mutants and 415 
pepQ mutants may be selected preferentially over atpE mutants in vivo during bedaquiline 416 
treatment because they strike the right balance between reduced susceptibility to bedaquiline and 417 
maintenance of fitness.  418 
Our findings may have implications for breakpoint selection for bedaquiline 419 
susceptibility testing. Although the bedaquiline MIC against the pepQ mutants is below the 420 
provisional susceptibility breakpoint of 0.5 µg/mL proposed by EUCAST (33), monotherapy 421 
with clinically relevant bedaquiline doses in mice infected with a pepQ mutant had limited 422 
efficacy. These findings and the limited clinical data available to date warrant careful monitoring 423 
of bedaquiline MICs and treatment outcomes and further consideration whether a lower 424 
breakpoint would better predict patient response to bedaquiline treatment. Polymorphisms in 425 
Rv0678 have recently been observed among isolates from patients that have not received 426 
bedaquiline or clofazimine and are not always associated with bedaquiline MICs that exceed the 427 
provisional breakpoint (28), and it remains unclear whether such Rv0678 mutations are 428 
associated with poorer clinical outcomes among patients receiving bedaquiline-containing 429 
regimens (6, 29). Thus, the clinical impact of the small shift in MIC conferred by pepQ 430 
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mutations remains to be determined. Further surveillance is required to identify Rv0678 and 431 
pepQ mutants and to correlate their presence with MICs and clinical outcomes among patients 432 
receiving therapy that includes one or both drugs. 433 
It is interesting to note that single nucleotide polymorphisms in pepQ were occasionally 434 
observed in clinical isolates that we have sequenced. In particular, pepQ:Ser66Pro was observed 435 
in two XDR-TB isolates (X16 and X23; Beijing strain family) and an MDR-TB isolate (R1792; 436 
LCC strain family) from the Western Cape of South Africa, all isolated prior to the introduction 437 
of bedaquiline (34). No other strains were observed to have mutations in pepQ among over 50 438 
clinical isolates from South Africa and South America. It is possible that use of clofazimine to 439 
treat MDR-TB in this region could have contributed to selective amplification of these mutants. 440 
However, this seems unlikely given limited usage of clofazimine in South Africa during the 441 
period in which such selection would have occurred. The clinical isolates with polymorphisms in 442 
pepQ were not available for drug-susceptibility testing. However, the presence of Rv0678 and 443 
pepQ mutations in isolates from patients naïve to bedaquiline and clofazimine raises the 444 
possibility that they may also be selected by other drugs used to treat TB or other infections. 445 
What is the function of pepQ in M. tuberculosis and how might loss-of-function result in 446 
reduced susceptibility to bedaquiline and clofazimine? While further characterization of the 447 
enzymatic activity of pepQ is clearly required before drawing conclusions, the genomic and 448 
structural characterization described here suggests pepQ is a proline-specific aminopeptidase and 449 
ortholog of pepP in E.coli and L. lactis and PapA (YqhT) in Bacillus subtilis (35). This is 450 
supported by homology in both genetic sequence and predicted protein structure. Although the 451 
DNA sequence homology is not particularly high, there is a high degree of conservation of 452 
amino acids in the predicted active site, including strict conservation of metal-binding residues 453 
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between pepQ and pepP from both E.coli and L. lactis. Moreover, each of these orthologous 454 
genes is situated next to and co-expressed with elongation factor P (EF-P; Rv2534c), one of the 455 
few universally conserved elongation factors (35). Conserved homologs also exist in other 456 
pathogenic mycobacteria (M. bovis, M. leprae, M. paratuberculosis (36). 457 
Proline-specific aminopeptidases are one of only 80 enzymes conserved in the 3 major 458 
kingdoms of life (37). Such high conservation may stem from the exceptional conformational 459 
rigidity that proline residues introduce into peptide chains, which presents challenges to 460 
proteolytic enzyme systems. For example, in E. coli, the essential methionine aminopeptidase 461 
(PepM) responsible for co-translational N-terminal methionine excision readily liberates the N-462 
terminal methionine when proline or an amino acid with similarly small side chain occupies the 463 
penultimate position. However, a proline in the third position inhibits PepM activity (38, 39), 464 
making pepP required for efficient N-terminal methionine excision in such cases (40).  465 
The conformational constraints of poly-proline motifs also present challenges during 466 
ribosomal peptide synthesis by stalling translation. As EF-P is required to prevent such stalling 467 
and promote efficient translation of poly-proline-containing peptides (41, 42), the genomic 468 
organization of a putative proline-specific aminopeptidase like pepQ with EF-P is likely no 469 
coincidence. Work in Gram-negative enteric pathogens has revealed that proteins with EF-P 470 
target motifs (and hence dependent on EF-P for optimal translation) are enriched for metabolic 471 
enzymes, membrane-associated proteins, transporters and two-component regulatory systems 472 
(43). The same appears true for M. tuberculosis. This system may have evolved for rapid 473 
remodeling of the cellular proteome in response to changing environmental conditions, such as 474 
carbon source (44, 45). The highly conserved organization of genes for proline-specific 475 
aminopeptidases and EF-P in bacteria thus supports a potential role for pepQ in regulating 476 
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maturation and/or turnover of specific proteins in a manner that is sensitive to the metabolic 477 
status of M. tuberculosis. 478 
Proline-specific aminopeptidases also have important roles in the utilization of exogenous 479 
and endogenous proteins as sources of essential amino acids useful for protein synthesis, energy 480 
production, osmoprotection and recycling of reduced cofactors. Proline itself is increasingly 481 
recognized as having a critical role in energy metabolism, redox control and bacterial virulence 482 
(46). In early transposon mutagenesis studies (19), disruptions of pepQ were observed to cause a 483 
growth defect (thus neither absolutely essential nor non-essential in vitro). More recent high-484 
resolution transposon-mutagenesis studies suggest that pepQ is conditionally essential when 485 
grown on glycerol as a carbon source, but not essential when grown on cholesterol (p-value 486 
<0.01 for comparison of transposon insertion counts) (47). This is interesting given recent 487 
evidence linking mycobacterial proline catabolism to protection from the toxic effects of 488 
methylglyoxal produced during growth on glycerol (48). If mutation of pepQ reduces 489 
intracellular availability of proline, this might increase susceptibility to methylglyoxal and 490 
reduce growth on glycerol. 491 
The mechanism by which pepQ mutations result in reduced susceptibility to bedaquiline 492 
and clofazimine is unclear. Rv0678 mutations appear to confer cross-resistance to bedaquiline 493 
and clofazimine via de-repression of mmpL5-mmpS5 (Rv0676c-Rv0677c), which encode an RND 494 
transporter capable of exporting bedaquiline and clofazimine (6, 7). Reversion of bedaquiline 495 
susceptibility of a pepQ mutant to that of its wild-type parent in the presence of efflux pump 496 
inhibitors suggests drug efflux is involved in the mechanism of resistance. However, unlike the 497 
mutations in Rv0678, the mutation in pepQ is not associated with over-expression of mmpL5 or 498 
mmpS5. One possibility is that pepQ mutations increase efflux through this transporter by a 499 
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different means, such as preventing degradation of MmpL5, which contains a Val-Pro-Pro 500 
stretch near the amino terminus.   501 
 In conclusion, we demonstrate that loss-of-function mutations in pepQ confer reduced 502 
susceptibility to bedaquiline and clofazimine. While the shift in susceptibility is relatively small, 503 
it is of similar magnitude to mutations in Rv0678 that have been selected in patients and mice 504 
receiving combination therapy including bedaquiline. Therefore, these results should provide the 505 
impetus to include pepQ in the genetic analysis of bedaquiline- and clofazimine-resistant strains 506 
identified during clinical usage. Further study of the biological function of pepQ in M. 507 
tuberculosis and the mechanism by which pepQ mutations confer reduced susceptibility is 508 
clearly warranted.   509 
 510 
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 691 
Table 1. Sequencing results for the resistant strains. 692 
Mouse 
number  
Treatment Coverage Completion MIC  (in µg/ml) Mutation 
B C 
B5 B 142.1x 99.25% 0.12 0.5-1 pepQ: L44P 
BC2 B+C 118.4x 99.20% 0.12 0.5-1 pepQ: +c in Ala14 
BC3 B+C 154.3x 99.43% 0.12 0.5-1 pepQ: +c in Ala14 
BC4 B+C 161.1x 99.14% 0.12 0.5-1 pepQ: -c in Arg271 
B = bedaquiline; C = clofazimine 693 
 694 
 695 
 696 
 697 
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Figure 1. Mean lung log10 CFU counts (± SD) after 4 and 8 weeks of treatment with 698 
bedaquiline- and clofazimine-containing regimens. Main figure does not include results from 699 
mice in which bedaquiline and clofazimine cross-resistant mutants were selected after 8 weeks of 700 
treatment: 2 and 3 mice from the B and BC groups with mean lung CFU counts of 3.22 ± 0.16 701 
and 2.12 ± 0.69 log10, respectively (inset). The CFU counts at the time of treatment initiation are 702 
indicated by Day 0. Abbreviations: R, rifampin; H, isoniazid; Z, pyrazinamide; B, bedaquiline; 703 
C, clofazimine; L, linezolid; Pa, pretomanid; E, ethambutol; M, moxifloxacin. 704 
 705 
 706 
 707 
 708 
 709 
Figure 2. Mean lung log10 CFU counts (±SD) (upper panels) and change in CFU counts (Week 4 710 
- Day 0) (lower panels) after 4 weeks of treatment in mice infected with the parental H37Rv 711 
strain (left panels) or the B5 mutant (right panels). CFU counts were not determined for 712 
untreated mice infected with the parental strain, which required euthanasia prior to the 713 
predetermined endpoint. Abbreviations: UT, untreated; H, isoniazid (10 mg/kg); C, clofazimine 714 
(20 mg/kg); B, bedaquiline (12.5, 25 or 50 mg/kg).  715 
 716 
Figure 3. Mean lung log10 CFU counts (±SD) (upper panels) and change in lung CFU counts 717 
(Week 4 – Day 0) (lower panels) after 4 weeks of treatment in mice infected with the parental 718 
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H37Rv strain (left panels), the B5 mutant (middle panels), or the complemented B5:pepQ strain 719 
(right panels). Abbreviations: UT, untreated; H, isoniazid (10 mg/kg); C, clofazimine (20 720 
mg/kg); B, bedaquiline (25 mg/kg). 721 
 722 
Figure 4. Location of mutations and domains in pepQ.  723 
 724 
Figure 5. Multiple amino acid sequence alignment for M. tuberculosis pepQ, L. lactis pepP, and 725 
E. coli pepP, constructed using ClustalW. Residues coordinating the Mn2+ ions are shown in red. 726 
Asterisks indicates positions which have a single, fully conserved residue. Colons indicate 727 
conservation between groups of strongly similar properties - scoring > 0.5 in the Gonnet PAM 728 
250 matrix.  729 
Periods indicate conservation between groups of weakly similar properties - scoring ≤ 0.5 in the 730 
Gonnet PAM 250 matrix.  731 
 732 
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